<DOC>
	<DOCNO>NCT00785044</DOCNO>
	<brief_summary>In past two year , subject participate medical research study use investigational drug call 123I-Iodine meta-iodobenzylguanidine ( 123I-mIBG ) ( pronounce `` 123 I oo dine-meta ioo doo ben zul gwan nid deen '' ) . The sponsor study ( GE Healthcare ) interest gather data concern heart failure subject cardiac event , since enrol original study . There injection radioactive image agent repeat image study .</brief_summary>
	<brief_title>Study Dosed With ( 123I-mIBG ) Identifying Subjects With Heart Failure Who Will Experience Adverse Cardiac Event</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>The subject Heart Failure subject sign informed consent MBG311 , MBG312 , MBG312C . The subject administer 123ImIBG MBG311 , MBG312 , MBG312C . The subject complete late planar image assessment ( minimum ) require protocol MBG311 , MBG312 , MBG312C . The subject agree allow investigator access medical record , include relate subject death occur . The subject withdraw withdrawn MBG311 , MBG312 , MBG312C . The subject consider losttofollowup ( 6 month without contact ) MBG311 , MBG312 , MBG312C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>MIBG</keyword>
	<keyword>Meta-Iodobenzylguanidine</keyword>
</DOC>